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Primary intraocular lymphoma (PIOL) is an ocular malignancy that is a subset of primary
central system lymphoma (PCNSL). Approximately one-third of PIOL patients will have
concurrent PCNSL at presentation, and 42e92% will develop PCNSL within a mean of 8
e29 months. Although rare, the incidence has been rising in both immunocompromised
and immunocompetent populations. The majority of PIOL is diffuse large B-cell lymphoma,
though rare T-cell variants are described. Recently, PIOL has been classified by main site of
involvement in the eye, with vitreoretinal lymphoma as the most common type of ocular
lymphoma related to PCNSL. Diagnosis remains challenging for ophthalmologists and
pathologists. PIOL can masquerade as noninfectious or infectious uveitis, white dot syn-
dromes, or occasionally as other neoplasms such as metastatic cancers. Laboratory diag-
nosis by cytology has been much aided by the use of immunocytochemistry, flow
cytometry, biochemical finding of interleukin changes (IL10:IL6 ratio > 1), and cellular
microdissection with polymerase chain reaction amplification for clonality. Use of several
tests improves the diagnostic yield. Approaches to treatment have centered on systemic
methotrexate-based chemotherapy, often with cytarabine (Ara-C) and radiotherapy. Use of
intravitreal chemotherapy with methotrexate (0.4 mg/0.1 mL) is promising in controlling
ocular disease, and intravitreal rituximab (anti-CD20 monoclonal antibody) has also been
tried. Despite these advances, prognosis remains poor.
ª 2014 The Authors. Published by Elsevier Inc. All rights reserved.CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
goo, MB, PhD, MRCOphth, FRCS (Ed), UCL Institute of Ophthalmology, Moorfields Eye Hos-
lds.nhs.uk (M.S. Sagoo).
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s u r v e y o f o p h t h a lmo l o g y 5 9 ( 2 0 1 4 ) 5 0 3e5 1 65041. Background control and to improve vision and radiotherapy to the brainThe designation intraocular lymphoma represents a hetero-
geneous group of malignant lymphocytic neoplasms arising
from either within the central nervous system (primary cen-
tral nervous system lymphoma - PCNSL) or outside the central
nervous system as metastasis from a non-ocular neoplasm
(secondary intraocular lymphoma).6 Primary intraocular
lymphoma (PIOL) is a subset of PCNSL where there is intra-
ocular involvement. Diagnosis poses a challenge to ophthal-
mologists and pathologists alike, as the disease can
masquerade as steroid-resistant ocular inflammation.171,174
Although a rare occurrence, the incidence of PIOL has
increased in the past 15 years, and prognosis for life remains
poor. We provide a comprehensive summary of the current
literature available on primary intraocular lymphoma and
highlight areas where further research is required.2. Definition
2.1. Primary intraocular lymphoma (PIOL)
Primary intraocular lymphoma (PIOL) was initially defined as
a subset of primary central nervous system lymphoma in
which lymphoma cells occur initially only in the eyes, without
evidence of disease in the brain or cerebrospinal fluid;22,32
although concomitant as well as subsequent intracranial
involvement occurs in many cases.37,54 The lymphoma cells
are seen within the vitreous and retina.
2.2. Secondary intraocular lymphoma
Secondary intraocular lymphoma arises outside the central
nervous system and metastasizes to the eye.22,84,94,142 The
secondary type, which typically has different clinical features
and prognosis,32 is outside the scope of the present review.
The lymphoma cells are present mainly in the uvea. Ocular
relapse of lymphoma of the testes, another immune-
privileged site, has been reported to mimic PIOL.207 Systemic
T-cell lymphoma with intraocular involvement shares some
of the ocular clinical features of typical B-cell PIOL.132,1353. Historical aspects
3.1. First description
The entity now known as PIOL was called malignant lym-
phoma of the uveal tract, by Cooper in 195147 and Givner in
1955.91 This terminology was replaced by the designation
ocular reticulum cell sarcoma.130
3.2. Early descriptions
Klingele and Hogan reported eight cases of ocular reticulum
cell sarcoma, four of which were diagnosed by craniotomy
when the signs of a brain tumor developed.130 A further report
detailed the use of radiotherapy to the eyes for local tumorbecause of frequent intracranial involvement.144
3.3. Current World Health Organization classification
and general overview of lymphoma nomenclature
Hematopoietic and lymphoid tissue tumors are classified
by the World Health Organization categories that include
myeloid, lymphoid, and histiocytic neoplasms. The system
uses the Revised European-American Lymphoma (REAL)
classification and is based on the principle that a classification
is a list of “real” disease entities that are defined by a combi-
nation of morphology, immunophenotype, and genetic and
clinical features.101,102
Broadly speaking, the classification divides primarily into
Hodgkin and non-Hodgkin lymphoid neoplasms. The latter
has two major categories: B-cell and T-/natural killer cell
neoplasms. The T- and B-cell neoplasms are further stratified
into lymphoblastic (precursor cell) and mature (peripheral) B-
and T-cell neoplasms. The latter are grouped according to
clinical presentationdleukemic (disseminated) and primary
extranodal and predominantly nodal (solid). The classification
considers lymphomas and lymphocytic leukemias of the
same cell type as one disease with different clinical pre-
sentations.101 Most PIOLs are of B-cell origin, and fall within
the category of diffuse large B-cell lymphomas.41,65,216 Isolated
PIOLs of T-cell origin occur rarely.17,25,50,86,92 Extranodal mar-
ginal zone lymphoma (mucosa associated lymphoid tissue B-
cell lymphomas) can also present with intraocular features,
often with a localized uveal mass with extraocular extension,
and is termed primary uveal lymphoma.46,53,56,594. Epidemiology
The exact epidemiology of PIOL, a rare malignancy, is not
known, and most data relate to the larger group of primary
central nervous system (CNS) lymphoma. These are esti-
mated to represent 4e6% of primary brain tumors and 1e2%
of extranodal lymphomas.85,106 The incidence in the USA has
tripled over the past 15 years,72,106,177 and this rise has been
mirrored in Europe.123 This increase was initially thought to
be due to increased numbers of immunocompromised pa-
tients, but since the introduction of highly active antiretro-
viral therapy, the incidence in patients with the acquired
immune deficiency syndrome (AIDS) has declined.93,155,172,189
Iatrogenic immunosuppression may also lead to
PIOL.39,49,120,126,173,218 The cause for the increased incidence in
immunocompetent patients is unknown.155 The Central
Brain Tumor Registry of the United States for the period
1998e2002 suggests that the incidence of CNS lymphoma has
dropped to 3.1% of brain tumors.29
PIOL usually occurs in adults from the third to the eighth
decades of life,19,27,107 although cases in infants39,211 and ad-
olescents are documented.163,183 The mean age of presenta-
tion is in the fifth and sixth decades of life.19,51,85,163,213 Some
reports suggest a sex bias, with women more commonly
affected than men by 2:115,21,163 or even greater.27,168 More
recently there appears to have been an increase of reported
s u r v e y o f o p h t h a lm o l o g y 5 9 ( 2 0 1 4 ) 5 0 3e5 1 6 505cases in men.168 There appears to be no racial predilection for
the disease.Fig. 1 e Composite color fundus photograph of the left eye
of a patient with PIOL. Note the hazy appearance of the
fundus due to the presence of vitreous cells, marked yellow
subretinal infiltrates with overlying retinal pigment
epithelial changes (“leopard spotting”) and accumulation
of subretinal fluid. Vitreous tap failed to provide sufficient
cells for diagnosis, so a vitrectomy with retinotomy and
subretinal aspirate was required to diagnose PIOL.5. Etiology
The etiology of PIOL/PCNSL remains an enigma. One hy-
pothesis suggests that in immunocompromised patients, a
mutation in the Epstein-Barr virus attracts lymphocyte cells
to the CNS, where transformation to neoplastic cells is
initiated.144 This is supported by the finding that Epstein-Barr
virus is invariably found in AIDS patients with PCNSL and
usually runs a more aggressive course,101 but the same as-
sociation in not documented in PIOL.160 Toxoplasma gondii
DNA has also been found in B-cell lymphoma cells in 2 out of
10 PIOL samples, leading to speculation on the role of this
organism.181 One suggestion is that an infectious antigen
driven B-cell expansion is the primary trigger, which then
becomes clonal.30 Another hypothesis poses haematological
transfer of neoplastic cells from nodal and extranodal sites to
ocular and central nervous system structures.21 In the che-
mokine hypothesis, B-cell chemokines may selectively
attract lymphoma cells from the choroidal circulation to the
retinal pigment epithelium (RPE). The B-cell chemokine re-
ceptors CXCR4 and CXCR5 were detected in lymphoma cells,
whereas their ligands BLC and SDF-1 were detected only in
the RPE.35 A disturbance in the factors contributing to the
immune privilege of the eye has also been implicated.316. Clinical features
6.1. Ocular features
One of the difficulties in the diagnosis of PIOL is its tendency to
mimic chronic posterior uveitis, even to the extent of an initial
response to steroid therapy. Symptoms at presentation
include blurred vision and/or floaters, but visual acuity is
usually better preserved than would be expected.21,37,107,133,213
Anterior segment inflammatory findings are frequently
absent,27 particularly scleral redness or posterior synechiae.
Theremaybe cells in the anterior chamber and the presence of
keratitic precipitates.22,54 Rare cases can present with infil-
tration of the iris or angle39,202 or as a pseudohypopyon.48,138
Examination of the posterior segment (Fig. 1) reveals vitri-
tis, which is present in the majority of cases.2,6,42,163 Vitreous
cells may form clumps, sheets, or strands with mild to mod-
erate haze. Another sign is the development of creamy lesions
with orange-yellow infiltrates that are deep to the retina or
RPE.2,6,22,27,42,88,110 They can give rise to a characteristic
“leopard skin” pigmentation overlying the mass.88 There may
be isolated subretinal lesions,134 sometimes with associated
exudative retinal detachment.27 Spontaneous resolution may
lead to RPE atrophywith subretinal fibrosis.68 Cystoid macular
edema is often absent, in contrast to uveitis cases of similar
cellularity,77 and vision is better than expected from the de-
gree of vitritis. The vitreoretinal form of the disorder can
mimic choroiditis or vasculitis.10,19 Optic nerve infiltration
may occur.90,103 Ocular disease is bilateral in 64e83% of cases,
although initially it may seem unilateral.27,42,107,163 Orbitalinvolvement in PIOL is exceptionally rare.149,157 Parikh et al
reported a systemic non-Hodgkin lymphoma simulating PIOL
with vitritis and a subretinal lesion, but without the choroidal
involvement typical of secondary intraocular lymphoma.162
The delay between a positive diagnosis and the onset of
ocular or neurological symptoms usually varies from
4e40months,27,99,107 although rapid progressionmay occur.2046.2. CNS features
Symptoms of CNS involvementmay emerge at any time of the
disease course and can be focal and/or diffuse.2,21,108,163,168 At
presentation of PIOL, 16e34% have CNS involvement.2,27,51,77
Tumors of the frontal lobe can induce behavioral changes
and alteration in cognitive function.10,98 Common focal
neurological findings are hemiparesis in 51% and cerebellar
signs, including ataxia, in 23%.106 A strong indicator of CNS
involvement is new-onset seizures.90 Lymphomatous men-
ingitis without intracerebral involvement is one variant.111
From 13% to 25% of patients with PCNSL have ocular signs
on diagnosis.27,80,104 Conversely, it is estimated that between
42% and 92% of PIOL cases go on to exhibit intracranial lym-
phoma within a mean interval of 8e29 months.2,27,51,85,163
Widespread dissemination of PCNSL can also occur in 7e8%
of patients, usually late in the course.1046.3. Primary uveal lymphoma
This less common entity involves any region of the uveal tract
locally. These were previously misnamed “reactive lymphoid
hyperplasia” and “uveal pseudotumors,” underlining their
less-aggressive clinical course.53,56 Cockerham and associates
re-evaluated pathological specimens of benign choroidal
reactive lymphoid hyperplasia archived at the Armed Forces
Table 1 e The Differential diagnosis of primary
Intraocular lymphoma
Inflammatory disorders
Posterior or intermediate uveitis or panuveitis
Multifocal choroiditis
Behc¸et disease
Acute posterior multifocal placoid pigment epitheliopathy
(AMPPE)
Multiple evanescent white dot syndrome
Birdshot choroidopathy
Serpiginous chorioretinopathy
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B-cell lymphomas by histology, immunocytchemistry, and
polymerase chain reaction,46 and the subtype is of an extra-
nodal marginal zone or mucosa associated lymphoid tissue
lymphoma.53 These eyes harbor a pale choroidal mass, rather
than the vitreoretinal involvement that occurs with PIOL.
Primary uveal lymphomas typically remain stable and pro-
duce minimal symptoms; if treatment is required, they are
very radiosensitive and carry a good prognosis.46,56 There is
often accompanying extraocular extension.53,156
We will concentrate on primary intraocular lymphoma of
the diffuse large B-cell type. Recently, there has been a sug-
gestion to replace the term PIOL with the anatomical location
of the lymphomatous infiltrates, namely, vitreoretinal, uveal,
iridal, or ciliary body.52
6.4. Differential diagnosis of PIOL
As it is a “masquerade syndrome”10,27,54,76,100,123 (Table 1), the
differential diagnosis of PIOL is wide and includes both in-
fectious5,8,27,44,70,87,96,147,154,161,178 and noninfectious uve-
itis.20,27,29,75,90,170,180,206 Metastatic cancers are usually pale
choroidal lesions associated with subretinal fluid in the
absence of vitreoretinal involvement. Sometimes metastases
with overlying mottled brown pigmentation at the level of the
retinal pigment epithelium mimic the “leopard skin” appear-
ance seen in PIOL. Amelanotic melanoma is also in the dif-
ferential diagnosis. Even in the over-60-years age group with
new-onset uveitis, PIOL remains a rare disorder.12,43,1517. Diagnostic techniques in PIOL
7.1. Imaging
7.1.1. Ocular
7.1.1.1. Fluorescein and indocyanine green angiography. In 44
patients with PIOL undergoing fluorescein angiography,27
there were punctate hyperfluorescent window defects in
55%, round hypofluorescent lesions in 34%, and vasculitis in
14%, although only 2% had angiographic evidence of cystoid
macular edema. A National Eye Institute study of 17 patients
with PIOL found granularity, blockage, and late staining at
the level of the RPE, with a notable lack of other angiographic
signs of inflammation such as macular edema and peri-
vascular staining or leakage.201 In another series,77 small
well-defined hypofluorescent lesions corresponding to the
infiltrates were seen in the early and late phases, indicating
masking of the choroidal fluorescence, a pattern present in
45% of PIOL eyes, compared with 2% of the uveitis cases.
Indocyanine green angiography showed small hypofluor-
escent lesions in the early phase, becoming less apparent in
the late phases. The hypofluorescent lesions were more
numerous on fluorescein than indocyanine green angiog-
raphy.77 Together, the fluorescein and indocyanine green
angiographic findings had a positive predictive value of 89%
and a negative predictive value of 85%.77 (Fig. 2).
7.1.1.2. Fundus autofluorescence. In 5 eyes with PIOL the
clinically observed brown “leopard spotting” over yellowlesions beneath the RPE had a bright hyperautofluorescence
appearance, whereas white lesions above the RPE were
hypoautofluorescent.17 This is thought to be the result of lip-
ofuscin in RPE cells.
7.1.1.3. Optical coherence tomography. Optical coherence
tomography (OCT) findings include nodular hyper-reflective
lesions in retinal pigment epithelium layer, reduced foveal
thickness compared to uveitis cases, and is useful for con-
firming the absence of cystoid macular edema.77,136 Recently,
the use of spectral domain OCT has demonstrated lympho-
matous subretinal or sub-RPE deposition.83,199 Further
research on the use of OCT to monitor treatment response of
such lesions is necessary, but its use is likely to be limited to
central, rather than peripheral, fundus involvement.
7.1.1.4. B mode ultrasound scan. Ophthalmic ultrasonography
can be used to narrow the differential where the posterior
segment is difficult to visualize. Abnormal ultrasonographic
findings are frequent, although none of the changes are spe-
cific for PIOL.163,196 The most common are vitreous debris,
retinal detachment, elevated chorioretinal lesions, and
widening of the optic nerve.
7.1.2. Neuroimaging
Magnetic resonance imaging (MRI) with contrast is more
sensitive than computed tomography (CT) for detecting
lymphomatous lesions in the CNS, but both are limited in
evaluating ophthalmic disease.131 CT and MRI show unifocal
or multifocal (in one-third of cases) periventricular, homoge-
nously enhancing lesions.16,115 With CT the lesions are iso-
dense or hyperdense, andwithMRI, the lesions are hypodense
on T1-weighted and hyperdense on T2-weighted images.37,89
PET/CT has been used to identify CNS lesions as well as
Fig. 2 e Color fundus photograph of the superonasal lymphomatous infiltrate from Figure 1 is shown (top left), with
indocyanine green angiogram (top right), highlighting masking of normal choroidal circulation. Fluorescein angiogram
(bottom left) shows initial masking by the deposit with some perilesional leakage. In the very late frame of the angiogram
(bottom right), the lesion stains with fluorescein and the retinal pigment epithelial changes and retinal vessels are seen in
relief.
s u r v e y o f o p h t h a lm o l o g y 5 9 ( 2 0 1 4 ) 5 0 3e5 1 6 507ocular activity, both of which take up the 2-[(18)F] fluoro-2-
deoxy-D-glucose dye, though the same lesions were identifi-
able either on MRI or on funduscopy.148
7.2. Blood testing
Blood tests should be used to rule out conditions in the dif-
ferential diagnosis, including markers of infectious and non-
infectious uveitis.37 Additionally a complete blood count and
human immunodeficiency virus test are useful.27
7.3. Biopsy
7.3.1. Vitreous and retina
Biopsy remains one of the hallmark procedures in diagnosing
PIOL.40,95,123 Tissue biopsy, especially of the vitreous, is per-
formed, especially if PCNSL lesions cannot be found on neu-
roimaging or when cerebrospinal fluid (CSF) evaluation
remains negative. Specimens can be obtained by fine needle
vitreous aspiration or pars plana vitrectomy.40 Multiple
biopsies may be required to reach a definite pathological
diagnosis.10,41,112,123,213 The main site of involvement is the
sub-RPE space (between RPE and Bruch membrane). The
retina, vitreous, and optic nerve head are affected to various
degrees.11,204 The uveamay show a reactive inflammatory cell
infiltrate, and uveal biopsies are often nondiagnostic.
Fine needle aspiration of the vitreous is performed with a
21- to 25-gauge needle inserted through the pars plana,
although the sample size is small. Generally this is a safe
clinical procedure, with a high success rate in differentiating
between infectious, inflammatory, and malignant causes of
uveitis.28 An initial diagnosis of intraocular malignancy or
infection was confirmed in 40% of patients.139 Pars planavitrectomy has several advantages, including improved vision
by clearance of vitreous debris and maximizing the sample
size,40,51,95,145,152,164,216 although extension of the lymphoma
through the sclerotomy port to the epibulbar space following
vitrectomy may occur.60
Vitreous biopsy specimens need to be transported quickly
for laboratory analysis.40,51,212 Lymphoma cells undergo
morphological degradation within 60 minutes, but an
appropriate preservative may be used if transport time ex-
ceeds this.41,212 The samples should be handled gently to
prevent cell degeneration that can make interpretation
difficult. In many cases, the paucity of the cells is the result
of corticosteroid treatment, which must be discontinued for
2 weeks before the procedure.212 A negative vitrectomy
sample is common, with the lymphoma subsequently diag-
nosed by brain biopsy when CNS involvement occurs.18,123
Fixation of the sample in HOPE (HEPES-glutamic acid
buffer-mediated Organic solvent Protection Effect) solution
may improve the yield and examination requires an experi-
enced cytopathologist.51,58 Communication with the pathol-
ogist before the procedure enables the optimum sample to
reach the laboratory, which vary in the techniques they have
available.
If subretinal lesions are present, a retinotomy can be per-
formed using the vitreous approach51,121 or they can also be
aspirated.72,104,135,136,176 Subretinal tumorsmay consist largely
of necrotic tissue, and so specimens are ideally taken from the
deeper part of the lesion, near the choriocapillaris, where
viable lymphoma cells are most likely to be found.52 Trans-
cleral biopsy using a partial scleral thickness flap is
described.40,95,121 If the eye is blind and painful or conservative
treatment is not possible, a diagnostic enucleation may
become necessary.194 Anterior chamber taps are sometimes
s u r v e y o f o p h t h a lmo l o g y 5 9 ( 2 0 1 4 ) 5 0 3e5 1 6508done,81 though most centers prefer vitreous cytology, as
cellular yield is usually better.
7.3.2. CSF and brain
A lumbar puncture to obtain CSF is indicated in suspected
PCNSL. Up to 25% of patients with identifiable lesions on MRI
will have positive CSF cytology.69,98 If a diagnosis of PCNSL can
be made from lymphoma cells found in CSF, and there is
simultaneous ocular involvement, then the need for ocular
tissue biopsy is less important. Stereotactic brain biopsies can
be used in patients with negative CSF findings who have
suspicious brain lesions on imaging studies.18,155
7.3.3. Cytological and histological findings
The diagnosis of PIOL requires a multidisciplinary approach.
From the pathologist’s viewpoint this involves morpholog-
ical assessment in conjunction with traditional immunocy-
tochemistry and molecular analysis (such as flow cytometry
and polymerase chain reaction [PCR] analysis). The tech-
niques used vary with the expertise of the pathologist and
the availability of the molecular technique. Pathologists
should be made aware of the clinical features, including the
cellularity of the vitreous. They can then decide on how to
aliquot out the sample. This will usually involve morpho-
logical assessment, immunocytochemistry (which can be
direct or involve formation into a cell block) and a molecular
technique to assess for clonality. Morphologically the typical
lymphoma cells are large B-cell lymphoid cells with scanty
basophilic cytoplasm, an elevated nucleus:cytoplasm ratio,
hypersegmented, round, oval, bean, or clover shaped nuclei
with a coarse chromatin pattern and prominent or multiple
nucleoli.2,51,123,137 (Fig. 3). The concordance between clinicalFig. 3 e Vitreous aspirate (A) and retinotomy specimen (B) showi
demonstrating positivity of the B-cell marker CD20 in the vitreofeatures and pathological diagnosis is as high as 96%.51 For
lymphoma, the positive predictive value of cytologic evalu-
ation was 99e100% and the negative predictive value was
61e81%.63,210 Sparse number of cells is the main reason for
an inconclusive result.78,123Vitreous specimens contain
many reactive T-lymphocytes, necrotic cells, debris, and
fibrin that can also confound the identification of malignant
cells.51
7.3.4. Immunocytochemistry and flow cytometry
The phenotyping of cells by their surface markers is useful
for identifying lymphomatous cells, particularly if cytology
is scanty.64,65,112,122,216 Immunocytological techniques use a
cell-mounted slide with antibodies directed at specific cell
markers.64,112 Flow cytometry works in a similar fashion,
except that the cells are separated using a fluorescence-
activated cell-sorter in a fluid medium. Immunocytology
increases the rate of diagnosis from 30% (using cytology
alone) to 70%,65 but requires more cells. Flow cytometry al-
lows for multiple monoclonal antibodies to be applied to an
aliquot of suspected lymphoma cells simultaneously, which
allows the use of a larger detection panel.169,221 Both of
these methods target monoclonal populations in PIOL, so
any contamination by heterogeneous population of B-cells,
such as inflammation secondary to malignancy, makes the
interpretation of results more difficult.41 Reactive inflam-
matory lymphocytes tend to be T-cells and express CD3 and
CD5. Hyalocytes (native vitreous cells) that express CD68
may also confound interpretation. In rare cases of T-cell
PIOL, immunocytochemistry markers for T-cells such as
those mentioned above are positive. Distinction, therefore,
from a reactive population by immunocytochemistry is notng multiple blue staining lymphoma cells. Lymphoma cells
us (C ) and retinotomy (D).
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mainly based on morphology and the demonstration of
clonality by molecular techniques.
7.3.5. Biochemical and PCR analysis
The production of several interleukins (IL) may assist in
differentiating intraocular lymphomas from chronic uveitis.
IL-10was reported to be a growth and differentiation factor for
malignant B-lymphocytes.9,125 IL-10 is elevated in the pres-
ence ofmalignant B-lymphocytes in PIOL/PCSNL, whereas IL-6
or IL-12 is elevated in inflammatory states.24,38,73,159 IL-10
concentrations above 150 pg/mL in undiluted aqueous or vit-
reous and of 50 pg/ml or more in diluted aqueous or vitreous
specimens were diagnostic of B-cell PIOL.150 Raised IL-10 in
the aqueous was found to have sensitivity of 0.89 and a
specificity of 0.93 for the diagnosis of PIOL, and was suggested
as a screening test.26 Moreover, PIOL is reported in some
studies to exhibit a high IL-10:IL-6 ratio (>1).24,38,210,214,219Wolf
et al found the ratio was 74.7% accurate (sensitivity 74%,
specificity 75.0%) for 35 patients with PIOL, with the reverse in
64 patients with uveitis.219 Wang et al reported sensitivity of
88% and specificity of 85% in 80 patients with uveitis or
PIOL.210 The use of the IL-10:IL-6 or IL-10:IL-12 ratios, however,
has been controversial as elevation may occur in eyes with
non-neoplastic uveitis.3,4,153 In one report the IL-10:IL-6 or IL-
10:IL-12 ratiowas elevated in 8 out of 14 vitreous samples from
non-neoplastic vitritis eyes.4 An IL-10:IL-6 ratio <1 has been
found in known cases of PIOL.4,23
Clonal expansion of B lymphocytes can be assessed using
immunoglobulin heavy chain (IgH) gene sequences, partic-
ularly in the third complementarity-determining region
(CDR3) of the variable region of IgH. The translocation of the
bcl-2 proto-oncogene is also involved in the genesis of some
lymphoma subtypes182,208,215 as well as expression of bcl-6
and bcl-10.208 Studies using PCR on systemic B-cell lym-
phoma1 and in PIOL105,124,182 reveal rearrangement of IgH
gene and bcl-2 proto-oncogene translocations. Cellular
microdissection and PCR amplification can be applied
together if malignant cells are too scanty to yield a greater
cell population from vitreous specimens.36,182,195,210 Chan
et al, in 60 cases of PIOL using this technique, showed rear-
rangement of the CDR3 of IgH gene in all.32 In an updated
report of 114 cases of B-cell PIOL, all cases had IgH gene
rearrangement, but this change was found in only 1 of 86
cases of uveitis.210 The size of the CDR3 region can also be
studied.97 PCR is not always reliable. In a series of 29 cases,
PCR was useful in 17, failed to detect gene rearrangements in
7, and in 5 cases there was insufficient material for PCR.150
Mmltiplex primers and semi-nested PCR increase the chan-
ces of primer annealing, thus enhancing the detection of
monoclonal population.79,140,198 PCR based studies have
suggested that the B-cells of PIOL are mature B-cells that
have undergone the germinal center reaction and the iden-
tical clone can be identified in ocular and cerebral tissues in
cases of CNS involvement.55,57,141
IgH gene rearrangements are a marker of clonality, rather
than malignancy, and have been found in samples with non-
neoplastic uveitis and may be absent in samples diagnosed as
PIOL by cytology and flow cytometry.7 These techniques
should be viewed as adjuncts, and more than one approachimproves diagnosis.30,191 The interpretation of any test should
be in the clinical context and involve a multidisciplinary
approach.8. Treatment of PIOL
8.1. Radiotherapy
Ocular irradiation with prophylactic CNS treatment is used in
an attempt to control PIOL, maintain vision, and prevent CNS
involvement.144 In a series of 12 patients with PIOL receiving
either chemotherapy alone, radiotherapy alone or a combi-
nation, there were no ocular relapses in any patients who had
received radiotherapy (30e35 Gy in 15 fractions) during a
mean follow-up of 19 months.15 Localized brain radiotherapy
is typically used first line to treat primary CNS lymphoma. If
vitreoretinal lymphoma occurs following treatment of CNS
lymphoma, whole eye radiotherapy may be added.
High-dose low fractionation CNS radiotherapy can lead to
neurotoxicity,69 including severe depression requiring elec-
troconvulsive therapy.61 Ocular complications of radiotherapy
were dry eye, cataract, and radiation retinopathy.15
8.2. Chemotherapy
Intravenous methotrexate alone achieved remission of PIOL
in 7 out of 9 patients,13 and intravenous high-dose cytarabine
has also been used with variable success.14,163,190 High dose
methotrexate is the most active drug, producing a response
rate of up to 72% when used alone and up to 94e100% in
combinations.16,175,193 Osmotic blood brain barrier disruption
to increase brain penetration of chemotherapy is associated
with non-sight threatening maculopathy.203
After high-dose methotrexate-based chemotherapy, cases
demonstrating relapse or refractory response treated with
high dose chemotherapy with thiotepa, busulfan, and cyclo-
phosphamide, followed by autologous peripheral blood stem
cell transplantation, obtained complete remission in 66 out of
79 patients.185e188 Median survival improved from 28 to
85 months in the high-dose chemotherapy group.185 Recur-
rent PIOL with PCNSL has been treated with intrathecal
methotrexate and cytarabine.146 Oral trofosphamide or
intravenous iraphosphamide may produce 6e18 months of
progression-free survival.116e119
8.3. Chemoradiation
Chemotherapy after radiation to the eyes and brain in PIOL,
initially used as a salvage treatment, may also be a primary
treatment.166,167,220 Intrathecal chemotherapy may be com-
bined with ocular and CNS radiation,42,197 though systemic
chemotherapy is also used. In another radiation treatment
study of 15 patients, of which 10 also received chemotherapy,
only one had local recurrence.113 Chemotherapy combined
with ocular irradiation resulted in better control of ocular
disease than either chemotherapy or non-ocular radio-
therapy,80 and in six PIOL cases receiving ocular radiotherapy
and systemic chemotherapy, initial remissionwas obtained in
all, with one patient progressing to PCNSL.11 Multimodality
s u r v e y o f o p h t h a lmo l o g y 5 9 ( 2 0 1 4 ) 5 0 3e5 1 6510treatment results in better disease control, but delayed
cognitive neurotoxicitymay occur with brain radiation.155 The
British Committee for Standards in Haematology suggests a
multimodality approach tailored to disease degree, severity,
and performance status of the patient.143
8.4. Ocular chemotherapy
8.4.1. Intravitreal methotrexate
Intravitreal chemotherapywith 0.4mgmethotrexate in 0.1mL
achieved local tumor control in relapsed PIOL,66,67,209 in ocular
relapse of PCNSL127 and as a primary treatment in combina-
tion with systemic chemotherapy,82 intrathecal chemo-
therapy184 or sub-Tenon steroid injections.200 Frenkel and
associates86 reported their 10-year results of using intravitreal
methotrexate as a primary treatment for PIOL of B- and T-cell
types and some secondary lymphomas. The intravitreal in-
jections were given twice weekly for 4 weeks, weekly for
8 weeks, and then monthly for 9 monthsdfor a total of 25
injections. Remission was reached after a mean of 6.4 in-
jections, with 95% of the eyes needing 13 injections or fewer.
Side effects included corneal epitheliopathy, which subsided
when the interval between injections increased. Drug resis-
tance may occur with repeated injections.179 Intravitreal
methotrexate has been combined with rituximab and meth-
otrexate based systemic chemotherapy with low-dose
(23.4 Gy) brain irradiation in four patients, giving disease-
free survival of up to 25 months.192
8.4.2. Intravitreal rituximab
Rituximab (1 mg in 0.1 mL), an anti-CD20 monoclonal anti-
body, is used intravitreally, based on its efficacy in systemic
lymphoma.114,128,129 Initial response was good with clearance
of PIOL, but subsequent relapse required intravitreal metho-
trexate and radiation.114 Statins have the potential to alter the
conformation of the CD20 receptor, which may change the
effect of rituximab.2179. Prognosis
The reporting of mortality from PIOL in the literature is
inconsistent because of diverse patient populations, variation
in treatment regimens, and small case series. Mortality rates
range between 9% and 81% in follow-up periods ranging from
12 to 35 months.2,11,15,27,42,51,71,85,113 Often, diagnosis is
delayed.
In PCNSL, median survival of patients treated with
radiotherapy alone or chemotherapy plus radiotherapy
ranges from 10e16 months, which can be extended to
greater than 30 months with methotrexate-based chemo-
therapy165 or by ifosfamide or trofosfamide.118 Grimm and
associates98 had a median progression free survival of
18 months and overall survival of 31 months in 221 patients
with PCNSL with intraocular involvement collected from 16
centers in 7 countries receiving a mix of therapies. They
concluded that ocular therapy improved local tumor control,
but had no effect on survival. In contrast, another series
found a survival advantage if PIOL was diagnosed before
CNS involvementd60 months survival versus 35monthsdalthough the group with initial ocular diagnosis
was younger.10910. Conclusion
When faced with a patient with possible PIOL, there are
several diagnostic and therapeutic dilemmas, and opinions
differ as to optimal management. It is important to bear a
“masquerade syndrome” in mind and have the appropriate
index of suspicion based on the clinical signs. Our approach is
to ascertain whether there are neurological features on ocular
presentation, which would determine the timing of neuro-
imaging of the brain and spine, usually with MRI. If no
neurological features are present, we would advise vitreous
and/or subretinal biopsy, in close liaison with the pathologist
as to how the specimen is to be handled. Once the diagnosis is
confirmed, our regimen is to undertake methotrexate-based
systemic chemotherapy with external beam radiotherapy to
both eyes and the brain if the patient’s general condition al-
lows. We realize, however, that in some cases only ocular
treatment is advised, either with intraocular chemotherapy or
radiotherapy. This approachmandates close follow-up for the
development of PCNSL. The ophthalmologist and the oncol-
ogist jointly monitor response to treatment. This includes
systemic examinations with regular MRIs and eye examina-
tions looking for signs of local relapse. If the latter occurs
without generalized involvement, then it is our practice to
undertake intravitreal methotrexate injections to achieve
local tumor control.
In PIOL, there are several contentious areas that merit
further research. These include cytologic diagnosis and
optimal therapy. New diagnostic modalities are likely to aid
quicker diagnosis. The optimal treatment regimen for PIOL
has yet to be established and requires a multidisciplinary
approach between the ophthalmologist, radiologist, patholo-
gist, and oncologist.34,158 Even experts in the diagnosis and
treatment of PIOL have contrasting views as to the use of
systemic versus intravitreal chemotherapy and the role of
irradiation.205 Intravitreal chemotherapy with more than one
agent may prove to be useful in ocular disease control. Suc-
cessful treatment modalities for PCNSL do not automatically
translate into successful therapies of PIOL.45 Given the rarity
of this disease, multicenter studies with standardized regi-
mens are more likely to yield useful clinical information.
Individualized targeted therapy33may evolve from the genetic
profile of each PIOL case, as well as advances in drug delivery
when new devices for ocular chemotherapy appear.7411. Method of literature search
Medline (1950 to end of June 2012) and Embase (1974 to end of
June 2012) databases were searched using the search terms
intraocular lymphoma and ocular lymphoma. Removing duplicate
articles, excluding articles that clearly related to extraocular
lymphoma, and removing foreign language papers provided a
total of 221 unique articles in English.
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